Market Overview - The Shanghai Composite Index closed at 3869.25 points, with a change of 0.10% [1] - The total trading volume of A-shares reached 1,280.495 billion yuan [1] Technical Analysis - A total of 175 A-shares experienced a death cross between the 5-day and 10-day moving averages [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Yuanjie Technology: 5-day MA down by 2.50% from the 10-day MA [1] - Shanshan Shares: 5-day MA down by 2.32% from the 10-day MA [1] - Zijian Electronics: 5-day MA down by 2.09% from the 10-day MA [1] Individual Stock Performance - Yuanjie Technology (688498): Increased by 3.59% with a trading turnover of 2.90% [1] - Shanshan Shares (600884): Increased by 0.22% with a trading turnover of 3.13% [1] - Zijian Electronics (301121): Decreased by 0.60% with a trading turnover of 3.19% [1] - Other notable stocks include: - WuXi AppTec (603259): Increased by 2.21% [1] - Fabon (300925): Increased by 1.67% [1] Summary of Stocks with Death Cross - Stocks with a death cross and their respective metrics include: - Yuanjie Technology: 5-day MA at 374.57 yuan, 10-day MA at 384.17 yuan [1] - Shanshan Shares: 5-day MA at 14.17 yuan, 10-day MA at 14.51 yuan [1] - Zijian Electronics: 5-day MA at 48.72 yuan, 10-day MA at 49.76 yuan [1] - The latest prices of these stocks are below their 10-day moving averages, indicating potential bearish trends [1]

Core Points - The Shanghai Composite Index is at 3876.54 points with a change of 0.29%, and the total trading volume of A-shares is 961.216 billion yuan [1] - A total of 158 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish trends [1] Group 1: Stocks with Significant Moving Average Crosses - Yuanjie Technology (688498) has a 5-day moving average of 374.30 yuan, which is 2.53% lower than its 10-day moving average of 384.03 yuan, with a current price of 357.58 yuan, down 6.89% from the 10-day average [1] - Shanshan Co., Ltd. (600884) shows a 5-day moving average of 14.14 yuan, down 2.43% from its 10-day moving average of 14.49 yuan, with a current price of 13.29 yuan, down 8.28% from the 10-day average [1] - ZhiJian Electronics (301121) has a 5-day moving average of 48.75 yuan, which is 2.05% lower than its 10-day moving average of 49.78 yuan, with a current price of 46.54 yuan, down 6.50% from the 10-day average [1] Group 2: Other Notable Stocks - WuXi AppTec (603259) has a 5-day moving average of 102.27 yuan, which is 1.97% lower than its 10-day moving average of 104.33 yuan, with a current price of 98.12 yuan, down 5.95% from the 10-day average [1] - Fabon Information (300925) shows a 5-day moving average of 25.73 yuan, down 1.78% from its 10-day moving average of 26.20 yuan, with a current price of 25.13 yuan, down 4.07% from the 10-day average [1] - Loka (603829) has a 5-day moving average of 21.29 yuan, which is 1.73% lower than its 10-day moving average of 21.67 yuan, with a current price of 20.07 yuan, down 7.37% from the 10-day average [1]

Core Insights - The proteomics research service industry in China is experiencing significant growth, with the market size projected to increase from 437 million yuan in 2019 to 1.822 billion yuan in 2024, and expected to reach 2.26 billion yuan by 2025, indicating a robust expansion trend [1][4][12] Industry Definition and Process - Proteomics is a biological science that studies the composition and changes of proteins in cells, tissues, or organisms. The main processes of proteomics analysis include protein extraction and purification, enzymatic digestion into smaller peptides, identification and quantification using mass spectrometry, and bioinformatics analysis [2][4] Industry Development Status - The application potential of proteomics technology spans basic scientific research, clinical translation, clinical diagnosis, and new drug development. The rapid growth in national investment in life sciences, basic medicine, and agricultural sciences has led to an increase in the types of technologies, customer types, and the number of customers in the proteomics research service sector [4][12] Industry Value Chain - The proteomics market has developed a complete value chain that includes upstream suppliers of mass spectrometry instruments and reagents, midstream proteomics service companies, and downstream end customers such as research institutions, universities, and hospitals [6][12] Competitive Landscape - The market share in China's proteomics research service industry is relatively concentrated, with the top five companies (CR5) holding 58.8% of the market. The leading companies include Jingjie Biotechnology, Zhongke New Life, BGI, Novogene, and Ouyi Biomedical, with respective market shares of 25.0%, 13.9%, 11.2%, 5.1%, and 3.6% [7][8] Key Companies - BGI focuses on providing research services and precision medicine solutions through multi-omics big data technologies, including gene testing and mass spectrometry analysis. Their DIA protein quantification analysis employs data-independent acquisition methods [8][10] - Jingjie Biotechnology specializes in proteomics technology services and antibody reagent products, serving clients in life sciences research, drug development, and clinical diagnostics. In 2022, they reported 836 clients and revenue of 195 million yuan [10][11] Industry Development Trends - The proteomics research service sector is expected to continue its rapid growth, driven by advancements in mass spectrometry and bioinformatics. The market is still in a relatively early stage compared to Europe and the US, with increasing applications in life sciences and medicine [12] - The trend in proteomics analysis is moving towards requiring less sample volume and achieving faster identification of a greater variety of proteins, with high-depth, high-throughput, and high-sensitivity analyses being key goals [12]

Core Viewpoint - The biopharmaceutical sector in China is experiencing a positive trend in innovation and investment, with significant growth in the approval of innovative drugs and a recovery in market conditions [1][2] Industry Summary - As of September 8, 2025, the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.89%, with notable gains from companies such as United Imaging Healthcare (688271) up 11.48% and BGI Genomics (688114) up 9.35% [1] - The "National Drug Safety Publicity Week" launched on September 1 highlights the positive development of the pharmaceutical industry, with 210 innovative drugs approved in the past five years, indicating a sustained growth trend [1] - Currently, approximately 30% of the world's innovative drugs under research are from China, showcasing the country's significant role in global pharmaceutical innovation [1] Company Summary - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index as of August 29, 2025, include United Imaging Healthcare (688271), BeiGene (688235), and others, collectively accounting for 50.27% of the index [2] - The Sci-Tech Biopharmaceutical ETF (588250) closely tracks the performance of the Sci-Tech Innovation Board Biopharmaceutical Index, reflecting the overall performance of representative biopharmaceutical companies listed on the Sci-Tech Board [2]

中信证券股份有限公司 关于北京诺禾致源科技股份有限公司 2025 年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北 京诺禾致源科技股份有限公司（以下简称"诺禾致源"或"公司"）向特定对 象发行股票并上市项目的保荐人，据《证券发行上市保荐业务管理办法》、 《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续督导 职责，并出具本持续督导半年度跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场检查 的工作要求。 2、保荐人已与公司签订承销保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展持续 督导工作，并于 2025 年 8 月 8 日对公司进行了现场检查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督导职 责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财务管理、会计核算和内部审计等内部控制制度； （3）查阅公司信息披露文件，查阅公司与关联方的 ...

Group 1 - The company announced the resignation of non-independent director Wang Qifeng due to adjustments in the corporate governance structure, but he will continue to work at the company [1][3] - Wang Qifeng was elected as the employee representative director during the company's second employee representative assembly held on September 1, 2025, with a term aligned with the fourth board of directors [1][4] - The resignation of Wang Qifeng will not affect the normal operation of the board or the company's daily operations, as it does not reduce the board members below the legal minimum [3][5] Group 2 - The company held its third meeting of the fourth board of directors on September 1, 2025, where members of the strategic committee and the remuneration and assessment committee were elected [2][6] - The remuneration and assessment committee consists of a majority of independent directors, with an independent director serving as the chairperson [6][7] - The term for the newly elected committee members will last until the end of the fourth board's term [6][7] Group 3 - The company convened its first extraordinary general meeting of shareholders on September 1, 2025, where all proposed resolutions were approved without any being rejected [8][9] - The meeting was conducted in compliance with relevant laws and regulations, with all board members and the board secretary present [10][11] - The resolutions included the cancellation of the supervisory board and amendments to the company's articles of association, which were passed with the required majority [10][11]

Group 1 - The company, Novogene, announced the convening of its first extraordinary general meeting of shareholders for 2025 on September 1, 2025 [2] - The meeting will review and approve the proposal regarding the revision and formulation of certain corporate governance systems [2]

Core Viewpoint - The company announced the election of Mr. Wang Qifeng as the employee director of the fourth board of directors during the employee representative meeting held on September 1, 2025 [1] Group 1 - The employee representative meeting took place on September 1, 2025 [1] - Mr. Wang Qifeng was elected as the employee director by all attending employee representatives [1]

Group 1 - The legal opinion letter is issued by Beijing Zhonglun Law Firm regarding the legality of the 2025 first extraordinary general meeting of shareholders of Beijing Novogene Bioinformatics Technology Co., Ltd [1][2] - The law firm confirms that it has reviewed the necessary documents and materials provided by the company for the issuance of the legal opinion [2][4] - The legal opinion focuses on the convening, holding procedures, qualifications of attendees, and voting procedures of the shareholders' meeting, without commenting on the content of the proposals discussed [4][9] Group 2 - The notice for the shareholders' meeting was properly communicated to all shareholders, including details on time, location, agenda, and registration methods [5][6] - The meeting was held at Novogene Building, with the chairman presiding, and voting was conducted both on-site and via an online platform [6][9] - A total of 2 shareholders attended the meeting in person, representing 214,810,348 shares, and 61 shareholders participated through online voting [6][7] Group 3 - The voting results showed that 218,029,592 shares were in favor of the proposals, with a small number of shares abstaining [9] - The law firm concludes that the convening, holding procedures, qualifications of attendees, and voting results of the shareholders' meeting are all in compliance with relevant laws and regulations [9]

Meeting Overview - The shareholder meeting was held on September 1, 2025, at the company's headquarters in Beijing [1] - A total of 63 ordinary shareholders attended, holding 218,106,509 voting rights, which represents 53.8457% of the company's total voting rights [1] Voting Process - The meeting was conducted in accordance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [1] - The meeting was chaired by the company's chairman, Mr. Li Ruiqiang, and attended by directors and supervisors [1] Resolution Results - The first resolution, a special resolution, was passed with over two-thirds of the voting rights in favor [1] - The second resolution was passed with 98.8901% of the votes in favor, indicating strong shareholder support [1] Legal Compliance - The meeting's procedures and voting results were confirmed to be in compliance with relevant laws and regulations, ensuring the legitimacy of the proceedings [2]